Wockhardt Ltd has informed that the Board of Directors of the Company at its meeting held on January 18, 2008, inter alia, has transacted the following:
1. Subject to the approval of shareholders, creditors and regulatory bodies the Board provided its in-principle approval to demerge the new drug discovery programme and the innovative new technologies R & D.
2. Subject to the approval of the shareholders and regulatory bodies the board approved raising of funds upto USD 200 million through issuance of equity / equity linked securities to expand its domestic and international business.
3. Convene an extra-ordinary general meeting of the members of the Company on February 20, 2008 for obtaining the approval of shareholders to raise funds upto USD 200 million.
1. Subject to the approval of shareholders, creditors and regulatory bodies the Board provided its in-principle approval to demerge the new drug discovery programme and the innovative new technologies R & D.
2. Subject to the approval of the shareholders and regulatory bodies the board approved raising of funds upto USD 200 million through issuance of equity / equity linked securities to expand its domestic and international business.
3. Convene an extra-ordinary general meeting of the members of the Company on February 20, 2008 for obtaining the approval of shareholders to raise funds upto USD 200 million.
No comments:
Post a Comment